Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 10 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Insilico Medicine Ip Limited has 15 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 13 distinct examiners, indicating that most examiners are managing a single case while a small number handle more. The prosecution is spread across 11 distinct art units, reflecting a diverse range of technical subject matter within the pharmaceutical sector. This distribution requires the applicant to manage multiple prosecution timelines simultaneously.
The busiest examiner for this portfolio is WILLIS, DOUGLAS M, who is responsible for 2 pending office actions. This examiner's workload represents a small portion of the 15 pending office actions currently active. Because the 13 distinct examiners operate across 11 distinct art units, practitioners must coordinate responses that are consistent across multiple specialized groups within the USPTO. The concentration of 2 pending office actions under WILLIS, DOUGLAS M provides a minor opportunity for streamlined communication.
With 15 pending office actions, the company faces a significant administrative challenge in maintaining a cohesive patent strategy. The involvement of 13 distinct examiners means that the company must be prepared for 13 unique approaches to prior art and obviousness rejections. Because the 15 pending office actions are spread across 11 distinct art units, practitioners must monitor for potential conflicts in prosecution across different technical divisions. This broad distribution underscores the complexity of the company's current engagement with the USPTO.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (42%) |
| §103 only | 4 (33%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KALLAL, ROBERT JAMES | 2 | 59.4% | +31.2% |
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
| HIBSHMAN, SARAH GRACE | 1 | 38.2% | +40.7% |
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| SKIBINSKY, ANNA | 1 | 39.1% | +29.3% |
| BRACERO, ANDREW ANGEL | 1 | 82.4% | +37.5% |
| LUO, JAMMY NMN | 1 | — | — |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800129 | ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS | BRACERO, ANDREW ANGEL | 33d |
| 18928814 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | DAVIS, BRIAN J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596888 | SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES | KALLAL, ROBERT JAMES | 25d overdue |
| 17911376 | RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY | SKIBINSKY, ANNA | 21d |
| 18721283 | METHOD AND MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | HIBSHMAN, SARAH GRACE | — |
| 18164160 | LOCAL STEPS IN LATENT SPACE AND DESCRIPTORS-BASED MOLECULES FILTERING FOR CONDITIONAL MOLECULAR GENERATION | KALLAL, ROBERT JAMES | — |
| 17835167 | ADVERSARIAL FRAMEWORK FOR MOLECULAR CONFORMATION SPACE MODELING IN INTERNAL COORDINATES | LUO, JAMMY NMN | — |
| 17479892 | METHYLATION DATA SIGNATURES OF AGING AND METHODS OF DETERMINING A METHYLATION AGING CLOCK | VANNI, GEORGE STEVEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596888 | SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES | KALLAL, ROBERT JAMES | 25d overdue |
| 17911376 | RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY | SKIBINSKY, ANNA | 21d |
| 17800129 | ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS | BRACERO, ANDREW ANGEL | 33d |
| 18837846 | MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | ROBINSON, MIKHAIL O'DONNEL | — |
| 18832564 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | CORNET, JEAN P | — |
| 18721283 | METHOD AND MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | HIBSHMAN, SARAH GRACE | — |
| 18705742 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | HASTINGS, ALISON AZAR | — |
| 18704366 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| 1614 | 1 |
| 1627 | 1 |
| 1693 | 1 |
| 1629 | 1 |
| 1621 | 1 |
| 2146 | 1 |
| 1635 | 1 |
| 2126 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18928814 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | DAVIS, BRIAN J | 1614 | §112DP | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18837846 | MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18832564 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | CORNET, JEAN P | — | §103 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18721283 | METHOD AND MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | HIBSHMAN, SARAH GRACE | 1693 | §102§103§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18705742 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | HASTINGS, ALISON AZAR | 1629 | §103Other | Final Rejection | — | Pending | Apr 29, 2024 |
| 18704366 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | O DELL, DAVID K | 1621 | DP | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18164160 | LOCAL STEPS IN LATENT SPACE AND DESCRIPTORS-BASED MOLECULES FILTERING FOR CONDITIONAL MOLECULAR GENERATION | KALLAL, ROBERT JAMES | 2146 | §101§103§112 | Non-Final OA | — | Pending | Feb 03, 2023 |
| 17911376 | RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY | SKIBINSKY, ANNA | 1635 | §101§103 | Final Rejection | 21d | Pending | Sep 13, 2022 |
| 17800129 | ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS | BRACERO, ANDREW ANGEL | 2126 | §103 | Non-Final OA | 33d | Pending | Aug 16, 2022 |
| 17835167 | ADVERSARIAL FRAMEWORK FOR MOLECULAR CONFORMATION SPACE MODELING IN INTERNAL COORDINATES | LUO, JAMMY NMN | 1686 | §101§103 | Final Rejection | — | Pending | Jun 08, 2022 |
| 17596888 | SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES | KALLAL, ROBERT JAMES | 1685 | §101§112 | Non-Final OA | 25d overdue | Pending | Dec 20, 2021 |
| 17479892 | METHYLATION DATA SIGNATURES OF AGING AND METHODS OF DETERMINING A METHYLATION AGING CLOCK | VANNI, GEORGE STEVEN | 1686 | §101§112DP | Non-Final OA | — | Pending | Sep 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInsilico Medicine Ip Limited has 12 pending office actions as of October 2026, spread across 10 art units and 11 examiners.
Robert James Kallal has the most, with 2 of Insilico Medicine Ip Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
